ArticleiScience2021
Human and mouse PD-L1: similar molecular structure, but different druggability profiles.
Article in iScience, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 55 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
55 citing papers in PubMed.
- Integrated Machine Learning and Molecular Simulation-Guided Discovery of Novel Small-Molecule PD-L1 Inhibitors.Pharmaceuticals (Basel, Switzerland) · 2026Article
- Efficacy of Bioengineered PD-L1 siRNA for Immunotherapy Against Non-Small Cell Lung Cancer Cells.Non-coding RNA · 2026Article
- Selenium-derived bioactive enablers for advanced therapies: From molecular redox modulation to broad-spectrum disease applications.Bioactive materials · 2026Review
- The co-delivery of Programmed Death 1 ligands enhances and prolongs rAAV-mediated gene expression in pre-immunized mice.Gene therapy · 2026Article
- Patient-Derived Models of Liver Cancer to Inform Clinical Treatment Paradigms: Recent Updates.Seminars in liver disease · 2026Review
- A 3D Co-Culture Model of Endometrial Carcinoma Cells with Peripheral Blood Immune Cells (PBMCs) to Study the Activity of Immune Checkpoint Inhibitors.Methods in molecular biology (Clifton, N.J.) · 2026Article
- Effects of adenosine triphosphate and reduced glutathione on biochemical, histopathological and immunofluorescence alterations associated with atezolizumab-induced cardiac tissue injury.Frontiers in pharmacology · 2026Article
- Targeting Folate Receptors for the Detection and Selective Treatment of Cancer: Advanced Precision Oncology in Practice.International journal of biological sciences · 2026Review
- Targeting PD-L1-CMTM6 interactions in myeloid cells triggers PD-L1 degradation and enhances cytotoxic T-cell expansion.Journal for immunotherapy of cancer · 2025Article
- Nanofilament immunotherapy induces potent antitumor vaccine responses.Journal for immunotherapy of cancer · 2025Article
- Universal Fab-Fc masked cytokine prodrug platform: αPD-L1/IL-15 prodrug activates CD44Journal for immunotherapy of cancer · 2025Article
- Characterization of Clinically Evaluated Small-Molecule Inhibitors of PD-L1 for Immunotherapy.ACS medicinal chemistry letters · 2025Article
- Comparison of the L3-23K and L5-Fiber Regions for Arming the Oncolytic Adenovirus Ad5-Delta-24-RGD with Reporter and Therapeutic Transgenes.International journal of molecular sciences · 2025Article
- PD-1Journal for immunotherapy of cancer · 2025Article
- Human GM-CSF/IL-3 enhance tumor immune infiltration in humanized HCC patient-derived xenografts.JHEP reports : innovation in hepatology · 2025Article
- PD-L1-CD80 interactions are required for intracellular signaling necessary for dendritic cell migration.Science advances · 2025Article
- Advancements in drug discovery: integrating CADD tools and drug repurposing for PD-1/PD-L1 axis inhibition.RSC advances · 2025Article
- Functional differences between rodent and human PD-1 linked to evolutionary divergence.Science immunology · 2025Article
- A bifunctional peptide-selenium nanocomposite for lysosomal degradation of PD-L1 and enhanced cancer immunotherapy.Frontiers in immunology · 2025Article
- Targeted Delivery of BMS-1166 for Enhanced Breast Cancer Immunotherapy.International journal of nanomedicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In the development of PD-L1-blocking therapeutics, it is essential to transfer initial
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.